Candriam S.C.A. has increased its stake in argenx SE by 5.8% during the third quarter, according to a recent filing with the Securities and Exchange Commission (SEC). The investment firm now owns a total of 48,200 shares of the biotechnology company, following the acquisition of an additional 2,633 shares. As of this filing, Candriam’s holdings in argenx are valued at approximately $35,550,000, representing about 0.08% of the company.
Several other institutional investors have also made significant moves regarding argenx shares. Adage Capital Partners GP L.L.C. raised its holdings by an impressive 114.3% in the second quarter, bringing its total to 297,113 shares valued at $163,775,000 after purchasing an additional 158,476 shares. Similarly, Franklin Resources Inc. boosted its position by 103.9%, owning 279,803 shares valued at $154,233,000 after acquiring 142,606 shares.
Balyasny Asset Management L.P. made a remarkable increase of 826.6%, now holding 89,296 shares worth $49,222,000 after buying 79,659 shares. Hudson Bay Capital Management LP also entered the market during this period, acquiring a new position valued at approximately $37,441,000. Additionally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. expanded its stake by 244.6%, now owning 87,414 shares valued at $48,184,000 after purchasing 62,044 shares. Overall, institutional investors now control approximately 60.32% of argenx’s stock.
Analysts Provide Insights on argenx
Analysts have been actively commenting on the performance of argenx shares. Recently, JPMorgan Chase & Co. raised their target price for the stock from $925.00 to $1,100.00, maintaining an “overweight” rating. This adjustment reflects growing optimism surrounding the company’s future prospects.
Wedbush reiterated an “outperform” rating with a price objective set at $1,000.00. In contrast, Robert W. Baird downgraded the stock from a “strong-buy” to a “hold” rating. TD Cowen also increased their price target from $800.00 to $1,146.00, while Truist Financial raised theirs from $950.00 to $1,030.00, both assigning a “buy” rating to the stock.
Currently, the consensus rating for argenx is classified as a “Moderate Buy,” with analysts suggesting a consensus price target of $986.78. This includes one “Strong Buy” rating, eighteen “Buy” ratings, four “Hold” ratings, and one “Sell” rating.
Current Performance of argenx SE
As of the latest trading session, argenx SE opened at $828.24. The stock has a fifty-day moving average of $842.75 and a two-hundred-day moving average of $795.35. The company boasts a market capitalization of $51.25 billion and a price-to-earnings (P/E) ratio of 35.56. Over the past year, argenx has seen a low of $510.05 and a high of $934.62.
Founded as a biotechnology company, argenx focuses on developing antibody-based therapeutics for severe autoimmune and neuromuscular diseases. Utilizing its proprietary SIMPLE Antibody platform, the company aims to create differentiated antibodies and engineered Fc regions, addressing significant medical needs. Its lead product, efgartigimod, marketed as Vyvgart, targets IgG-mediated disorders by reducing circulating IgG antibodies.
As institutional interest continues to grow and analysts express optimism, argenx SE remains a focal point in the biotechnology sector. Investors and stakeholders will be keen to monitor the company’s developments and market performance in the coming months.
